I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

*S*imply defined, probiotics are live bacteria that confer a health benefit to the host. The term "Probiotic" was initially coined to oppose the term "Antibiotic" by Lilley and Stillwell in 1965. The World Health Organization (WHO) recognizes probiotics to be the next, most important immune defense system in the event that current antibiotics become useless because of the development of bacterial resistance. This concept has fuelled research for using probiotics in medicine and dentistry.

The organisms that have been used in the past as probiotics are certain strains of *Lactobacillus* and *Bifidobacteria*.\[[@ref1]\] Some of the mechanisms of action of these probiotics include the production of bacteriocin-like inhibitory substances and the alteration of local pH, competing for nutrients, forming physical barriers, and stimulating immune response.\[[@ref2]\] Within the field of endodontics, the traditional method of treatment has been to eliminate the bacteria present in the root canal system. When root canal therapy fails, the presence of bacteria is almost always present. *Enterococcus* faecalis and *Candida albicans* are particularly found consistently in posttreatment endodontic disease.\[[@ref3]\] Endodontic therapy aims to remove bacteria through chemomechanical methods.

To our knowledge, probiotics work is sparse in terms of their therapeutic effect in the treatment of endodontic disease. Recently, probiotics have been introduced in dentistry for the treatment or prevention of disease. Experimental studies and clinical trials have demonstrated that certain gastrointestinal bacteria may control the growth of some oral microorganisms, including those cariogenic species associated with dental decay. Oral administration of probiotics has also been explored in the control of periodontal disease by reducing plaque levels and gingival inflammation.\[[@ref4][@ref2]\] The purpose of this study is to evaluate the potential use of probiotic therapy as an adjunct in endodontic therapy along with its effect on the reduction or elimination of apical periodontitis.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

P[ROBIOTIC STRAIN SELECTION]{.smallcaps} {#sec2-1}
----------------------------------------

Because of financial limitations, individual probiotic strains could not be purchased from ATCC (American Type Culture Collection). After extensive research, two commercial probiotic cocktails Ecobion and Darolac were used in this study. The probiotic cocktails were delivered in wrapped ice packaging to preserve viability of the organisms. Upon arrival, the probiotics were stored in a refrigerator at 30°F. Probiotic strains were isolated as per the manufacturer\'s instructions \[[Table 1](#T1){ref-type="table"}\].

###### 

Revival of probiotics from commercial products

![](JISPCD-7-46-g001)

P[ATHOGENIC STRAIN SELECTION]{.smallcaps} {#sec2-2}
-----------------------------------------

*E. faecalis* ATCC 29212 was chosen for this study after extensive literature review, which revealed that this organism possesses multiple properties leading to its key role as an endodontic pathogen.\[[@ref5][@ref6]\]

*C. albicans* ATCC 10231 was chosen as another pathogenic test organism because of its biphasic nature, which allows it to be the universal co-aggregate in biofilms; it is the most frequently isolated fungus from root filled teeth with apical periodontitis.\[[@ref7]\]

P[HASE 1: TESTING FOR PROBIOTIC EFFICACY AGAINST E. FAECALIS AND C. ALBICANS]{.smallcaps} {#sec2-3}
-----------------------------------------------------------------------------------------

### Planktonic stage evaluation {#sec3-1}

*Lactobacillus* strain was isolated from each of the commercially available probiotic capsules viz. Ecobion (E2) and Darolac (D4). These strains were further evaluated using different microbiological techniques.

**Agar Cup Method**

0.5 ml of requisite test pathogen culture of 0.1 optical density (OD) at 620 nm was inoculated into 20 ml of molten sterile agar cooled to 45°C ± 2°C. The solutions were mixed thoroughly and poured into a sterile empty petridish and allowed to solidify. Circular wells of 8 mm diameter were punched using a sterile steel cork borer in each of the poured plates. Appropriately diluted test samples were added to the above-punched wells. The volume of the solution added to each well was 100 μl. The plates were incubated in an upright position at 37°C for 24 hours under aerobic conditions. Post incubation, zone of inhibition (ZOI) was measured (mm).

**Extraction of cell-free supernatant (CFS)**

The pure isolate of *Lactobacillus* spp. was propagated in 100 ml flask containing MRS broth (pH 6.0) and incubated at 37°C for 72 hours under microaerophilic conditions. The supernatant that may contain crude bacteriocin, a cell-free solution, was obtained by centrifuging the culture at 10000 rpm for 20 minutes at 4°C. After centrifugation, the supernatant was collected in a fresh sterile tube and the pellet was discarded. The crude CFS was adjusted to pH 6.0 using 1 N NaOH prior to testing and crude CFS used as well. The crude CFS diluted to 1:2 used for testing.

P[HASE 2]{.smallcaps}: B[IOFILM STAGE TESTING; INTRACANAL DELIVERY VEHICLE FOR PROBIOTICS]{.smallcaps} {#sec2-4}
------------------------------------------------------------------------------------------------------

### Controls testing {#sec3-2}

Probiotic isolates (E2 and D4), pathogens (*C. albicans* ATCC 10231and *E. faecalis* ATCC 29212) stocks were prepared in tryptic soy broth (TSB) broth and adjusted to a respective OD at 600 nm using UV spectrophotometer \[[Figure 1](#F1){ref-type="fig"}\]. Nine millilitre of poloxamer was placed in a test tube and 500 µl of the above adjusted cultures were added and vortexed at 4°C in a refrigerated environment to allow homogenous mixing of poloxamer and microorganisms. This mixture was then incubated for 48 hours in an incubator at 37°C under aerobic conditions. After 48 hours, serial dilutions were prepared and plated on Brain Heart Infusion (BHI) agar plates to evaluate colony forming units (CFU) of the organisms. Serial dilutions were made by adding 1 ml of poloxamer mix to 9.0 ml sterile saline, followed by serially diluting the mixture by 1 ml into 9.0 ml sterile saline till 10^−8^ dilution followed by incubation at 37°C for 72 hours under aerobic conditions.

![Control testing poloxamer mixture](JISPCD-7-46-g002){#F1}

### Testing for probiotic/pathogenic organism poloxamer mixture {#sec3-3}

9 ml of the poloxamer mixture was placed in a test tube along with 0.5ml of *E. faecalis* ATCC 29212 (OD, 0.252). Then, 500 µl of the test probiotic strain (E2 OD, 0.346; D4 OD, 0.328) was added. Nine millilitre of the poloxamer mixture was placed in a test tube along with 500 µl of *C. albicans* ATCC 10231 (OD, 0.256). Then, 500 µl of the test probiotic strain (E2 OD, 0.346; D4 OD, 0.328) was added. After 48 hours of incubation, serial dilutions of the pathogenic biofilm samples were prepared and plated on BHI agar plates to evaluate CFU of the organisms.

Serial dilutions were made by adding 1 ml of poloxamer mix to 9.0 ml sterile saline, followed by serially diluting the mixture by 1 ml into 9.0 ml sterile saline till 10^8^ dilution. Plating was done by adding 1 ml of the dilutions onto BHI agar plates followed by incubation at 37°C for 72 hours aerobically. CFU were evaluated for all test groups and compared to controls based on the prepared dilutions to reflect the actual number of probiotics and pathogenic organisms in each group \[[Figure 2](#F2){ref-type="fig"}\].

![Testing for probiotic (E2 and D4) against pathogenic organism (*E. faecalis* ATCC and *C. albicans* ATCC) in poloxamer mixture](JISPCD-7-46-g003){#F2}

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

R[ESULT OF AGAR CUP/WELL DIFFUSION METHOD]{.smallcaps} {#sec2-5}
------------------------------------------------------

The inhibitory activity of the test strain was considered significantly positive if the ZOI produced by the test strain against the indicator strain (endodontic pathogen) was at least 10 mm.

The cell free suspensions (CFS) of these 2 isolates were tested against *E. faecalis* ATCC 29212 and *C. albicans* ATCC 10231 using agar cup/well diffusion method. The CFS of the two strains were used in 3 forms, i.e. (a) neat/crude; (b) CFU diluted to 1:2; and (c) CFS adjusted to pH 6.0.

\(a\) The crude CFS of both E2 and D4 when tested against *E. faecalis* ATCC 29212 showed antimicrobial activity with an average ZOI of 16.5 mm.

\(b\) The 1:2 diluted crude CFS of both E2 and D4 when tested against *E. faecalis* ATCC 29212 demonstrated antimicrobial activity with an average ZOI of 12 mm.

\(c\) However, when the crude CFS was adjusted to pH 6.0, it showed no activity against *E. faecalis* ATCC 29212 and *C. albicans* ATCC 10231.

\(d\) All the three forms of CFS did not show any antimicrobial activity against *C. albicans* ATCC 10231 \[[Table 2](#T2){ref-type="table"}; Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}\].

###### 

Zone of inhibition of Probiotic samples against *E. faecalis* and *C. albicans*
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![Agar cup method test of Ecobion (E2) CFS against *E. faecalis* and *C. albicans*](JISPCD-7-46-g005){#F3}

![Agar cup method test of Darolac (D4) CFS against *E. faecalis* and *C. albicans*](JISPCD-7-46-g006){#F4}

A[NTIBACTERIAL EFFICACY OF PROBIOTICS ON BIOFILM MORPHOLOGICAL STAGE OF ENDODONTIC PATHOGENS]{.smallcaps} \[T[ABLES]{.smallcaps} [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}\] {#sec2-6}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Testing of probiotic Ecobion (E2) against *C. albicans* ATCC 10231 and *E. faecalis* ATCC 29212, poloxamer mixture

![](JISPCD-7-46-g007)

###### 

Testing of probiotic Darolac (D4) against *C. albicans* ATCC 10231 and *E. faecalis* ATCC 29212, poloxamer mixture

![](JISPCD-7-46-g008)

The two *Lactobacillus* strains were further evaluated for their efficacy to inhibit biofilm formation by endodontic pathogens. It was observed that

\(a\) Ecobion-E2 and Darolac-D4 when tested against *E. faecalis* ATCC 29212 were found to show a reduction of 90.60% and 77.51%, respectively.

\(b\) Ecobion-E2 when tested against *C. albicans* ATCC 10231 for its efficacy were found to show 83.79% reduction.

\(c\) However, Darolac-D4 when tested against *C. albicans* ATCC 10231 for its efficacy were found to show no reduction.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Probiotic use has been studied for the treatment of oral health problems. Specifically, the use of probiotics has been explored to aid in the treatment of periodontal problems, halitosis, and caries prevention.\[[@ref2][@ref8]\] The most commonly used strains belong to the *Lactobacillus* and *Bifidobacterium* genera that are commonly found in the oral cavity, including caries lesions.\[[@ref9][@ref10]\] These were the first probiotic species to be introduced into research.\[[@ref11]\] *Lactobacillus rhamnosus GG*, ATCC 53103 has been proposed to reduce the risk for caries by producing a growth inhibitory substance against *Streptococcus sobrinus*.\[[@ref10]\] Other strains of probiotics in the oral cavity include *L. acidophilus*, *L. casei Shirota*, *L. paracasei*, *L. casei*, *L. johnsonii*, *L. reuteri*, *Propionibacterium*, *Weisella cibaria*.\[[@ref12]\]

Probiotic approach has not yet been extensively evaluated for use in endodontic therapy. Endodontics is the branch of dentistry that is concerned with the morphology, physiology, and pathology of the human dental pulp and periradicular tissues. It has been established that the primary etiology of endodontic infections is bacteria.\[[@ref13]\] Primary infections of the necrotic pulp tissue are generally composed of a mixed bacterial community dominated by anaerobic Gram-negative bacteria.\[[@ref14]\] Persistent infections tend to be dominated by a more specific community of bacteria. These bacteria are anaerobic and Gram positive, in particular *E. faecalis*.\[[@ref15]\]

The biphasic nature of *C. albicans* allows it to be the universal co-aggregate in biofilms and is the most frequently isolated fungus from root filled teeth with apical periodontitis. *E. faecalis* appears to be highly resistant to the medicaments used in treatment and is one of the few microorganisms shown *in vitro* to be resistant to calcium hydroxide because of its proton pump.\[[@ref16]\] It can also survive as a single organism without the support of other bacteria. In addition, *E. faecalis* has the ability to form a surface attached microbial community known as biofilm. This allows it to be protected from host defenses as well as systemic treatment. Different methods of combating *E. faecalis* were explored through the use of different irrigants. "Out of the box" treatments were evaluated for use against *E. faecalis* such as the use of passion fruit juice as an endodontic irrigant,\[[@ref17]\] as well as the use of lasers and phytomedicine.\[[@ref18][@ref19]\]

Probiotics hold a potential avenue of more common and broad use for antibacterial treatment in the future. In this study, an innovative approach which might aid in increasing the success of endodontic therapy was investigated. This innovative approach involves bacteriotherapy by allowing probiotic organisms to eliminate pathogenic organisms, either by outcompeting/immune modulation or by secreting antimicrobial substances such as peroxides.\[[@ref20]\]

This study involved two phases: phase one (discovery phase) and phase two (application phase). Phase one was an agar cup method test utilized to determine the sensitivity or resistance of the pathogenic bacteria (*E. faecalis* or *C. albicans*)to various probiotic challenges. The pathogenic organisms were grown on blood agar in the presence of test probiotic groups placed in the wells punched in the agar plate. The absence of growth around the well was an indirect measure of the ability of the test probiotic groups to inhibit growth/out compete the pathogenic organisms *E. faecalis* or *C. albicans*. ZOI was seen for *E. faecalis* but not for *C. albicans*. Thus, in the planktonic stage, both the probioic groups exhibited antimicrobial activity against *E. faecalis*.

Phase two was considered to be the application portion of the study, suggesting a novel delivery vehicle for probiotics into the root canal system by utilizing 30% poloxamer 407 (also known as pluronic F-127) mixed with MRS or TSB broth containing the probiotics. Poloxamer has been utilized in the biofilm stage testing of microorganisms. Poloxamer 407 showing inverse thermosensitivity is soluble in aqueous solutions at low temperatures (mainly 4°C), but forms a gel at higher temperatures.\[[@ref21]\] These properties make them an ideal delivery vehicle for use as an intracanal medicament between interappointment visits. Other advantages of poloxamer 407, which make it ideal for use in the root canal system, is that it has already been employed in vehicles for fluorinated dentifrices and as a dental gel product for treating patients with sensitive gums and teeth. It would be an ideal solution for apical periodontitis which is the main cause for endodontic failure.\[[@ref21]\]

The CFU/ml count results for this study revealed significant reduction of *E. faecalis* colony counts for probiotic groups E2 and D4 when mixed in equal amounts with *E. faecalis* in the 30% poloxamer/MRS broth formula when compared with controls, however, CFU/ml counts for *C. albicans* in probiotic group E2 was significant whereas D4 showed no activity when mixed in equal amounts with *C. albicans* in the 30% poloxamer/MRS broth formula when compared with controls. Thus, in the biofilm stage, probiotic groups demonstrated a decrease in CFU/ml count of the pathogenic organisms *E. faecalis* but not *C. albicans*.

Because of the financial limitations, commercial probiotics were utilized, and probiotic organisms were extracted either in groups or individually according to manufacturer\'s instruction. There have been no studies involving the use of probiotics in endodontics. The effective CFU count needed to eliminate or outcompete the pathogenic organisms is unknown. However, on a positive note, the manufacturer was contacted to determine the method for the extraction of probiotic species from commercial samples. Probiotics and pathogenic organisms E. feacalis and *C. albicans* were tested in both planktonic and biofilm stages. Thus a standardized *in-vitro* study was designed.

The Human Microbiome theory is gaining acceptance in medicine but has not yet been evaluated in endodontics. Maintaining or restoring equilibrium with probiotics may show promising results in endodontic therapy. Although sterility of the endodontic system is deemed necessary for endodontic success, and achieving complete sterility is currently impossible under normal conditions.\[[@ref20]\] Probiotics used against test organisms evaluated *in vitro* in both the planktonic and biofilm stages, in terms of measurement of ZOI, is an acceptable method of evaluation of efficacy of the probiotics against pathogenic organisms. This pilot study demonstrated that probiotics can be researched further as an adjunct in endodontic therapy.

The protocol for the probiotic medicament would be, instead of a microbial "elimination therapy" by the use of antimicrobial agents, substituted by a microbial "replacement therapy." Instead of attempting to eliminate pathogenic organisms by antimicrobial agents, probiotics would eliminate the endodontic pathogenic flora, allowing a more favorable/biocompatible environment using it as an intracanal medicament. This is in light of current and emerging findings in microbiology, which states that a reasonable and better approach to addressing and dealing with microbial infection should be to maintain a state of equilibrium within the Human Microbiome. In addition to eliminating and outcompeting the pathogens that originally entered from the carious process, probiotic organisms could not only eliminate disease causing bacteria but might also prevent their re-establishment after treatment has been completed, thus decreasing the incidence of endodontic failure.\[[@ref20]\]

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

This pilot study demonstrated that probiotics show a potential in root canal therapy. Despite significant promises, endodontic works are sparse and need validation by further *in-vitro*, *in-vivo* research and large randomized trials. This will determine the full potential of bacteriotherapy and its application in endodontics.
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